These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 15082419)
1. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Ran J; Hirano T; Adachi M Am J Physiol Endocrinol Metab; 2004 Aug; 287(2):E227-32. PubMed ID: 15082419 [TBL] [Abstract][Full Text] [Related]
2. [Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats]. Ran JM; Lao GC; Xu G; Xie B; Zhang Y; Liu W; Feng Q; Guo J Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1557-61. PubMed ID: 18956640 [TBL] [Abstract][Full Text] [Related]
3. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Okada K; Hirano T; Ran J; Adachi M Hypertens Res; 2004 Apr; 27(4):293-9. PubMed ID: 15127887 [TBL] [Abstract][Full Text] [Related]
4. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148 [TBL] [Abstract][Full Text] [Related]
5. Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis. Yokozawa J; Sasaki T; Ohwada K; Sasaki Y; Ito JI; Saito T; Kawata S J Gastroenterol; 2009; 44(6):583-91. PubMed ID: 19365601 [TBL] [Abstract][Full Text] [Related]
6. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Mizuno M; Sada T; Kato M; Koike H Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043 [TBL] [Abstract][Full Text] [Related]
7. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344 [TBL] [Abstract][Full Text] [Related]
8. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Ran J; Hirano T; Adachi M Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E955-61. PubMed ID: 15213064 [TBL] [Abstract][Full Text] [Related]
9. Vitamin A status affects obesity development and hepatic expression of key genes for fuel metabolism in Zucker fatty rats. Zhang Y; Li R; Li Y; Chen W; Zhao S; Chen G Biochem Cell Biol; 2012 Aug; 90(4):548-57. PubMed ID: 22554462 [TBL] [Abstract][Full Text] [Related]
10. Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats. Sugimoto K; Kojima K; Baba M; Yasujima M J Hypertens; 2011 Jul; 29(7):1337-46. PubMed ID: 21602711 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. Ran J; Hirano T; Adachi M J Hypertens; 2005 Aug; 23(8):1525-30. PubMed ID: 16003179 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Ran J; Hirano T; Fukui T; Saito K; Kageyama H; Okada K; Adachi M Metabolism; 2006 Apr; 55(4):478-88. PubMed ID: 16546478 [TBL] [Abstract][Full Text] [Related]
13. Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats. Igarashi M; Hirata A; Nozaki H; Kadomoto-Antsuki Y; Tominaga M Diabetes Res Clin Pract; 2007 Mar; 75(3):267-77. PubMed ID: 16934905 [TBL] [Abstract][Full Text] [Related]
14. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512 [TBL] [Abstract][Full Text] [Related]
15. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds. Wasan KM; Risovic V; Yuen VG; McNeill JH J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173 [TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. Muñoz MC; Giani JF; Dominici FP; Turyn D; Toblli JE J Hypertens; 2009 Dec; 27(12):2409-20. PubMed ID: 19901849 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin II type 1 receptor antagonists prevent glucose-induced increases in islet blood flow in rats. Iwase M; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M Scand J Clin Lab Invest; 2009; 69(1):145-50. PubMed ID: 18937099 [TBL] [Abstract][Full Text] [Related]
19. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044 [TBL] [Abstract][Full Text] [Related]
20. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. de Vinuesa SG; Goicoechea M; Kanter J; Puerta M; Cachofeiro V; Lahera V; Gómez-Campderá F; Luño J J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S206-12. PubMed ID: 17130263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]